-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Quizartinib for Acute Myeloid Leukemia

Program: Special-Interest Sessions
Session: ASH-FDA Joint Symposium II: Striking a Balance - Benefit-Risk in Drug Approvals
Monday, December 11, 2023, 2:45 PM-4:15 PM

Joseph Wynne, MD, PhD

DHM1/CDER, Food and Drug Administration, Silver Spring, MD

Disclosures: No relevant conflicts of interest to declare.

See more of: ASH-FDA Joint Symposium II: Striking a Balance - Benefit-Risk in Drug Approvals
See more of: Special-Interest Sessions
<< Previous Presentation | Next Presentation >>